甲氧西林耐药金黄色葡萄球菌感染治疗与防控  

Treatment and prevention of methicillin-resistant Staphylococcus aureus associated infections

作　　者：周晓兰[1] 李光辉[2] 

机构地区：[1]复旦大学附属华山医院国际医疗中心,上海200040 [2]复旦大学附属华山医院抗生素研究所,上海200040

出　　处：《中国医学前沿杂志（电子版）》2017年第4期13-16,共4页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：甲氧西林耐药金黄色葡萄球菌(methicillin-resistant Staphylococcus aureus,MRSA)是临床上一类重要的耐药菌,MRSA感染可造成患者死亡率上升、住院天数和医疗费用增加等,应受到高度重视。临床上,万古霉素依然是抗MRSA感染的主要药物,但多种抗MRSA感染新药的问世,使治疗有了更多选择。MRSA传播和感染预防的策略分为基本策略和特殊策略。Methicillin-resistant Staphylococcus aureus （MRSA） is a common pathogen for hospital aquired infection. Great emphasis on MRSA associated infections is intimately related to higher mortality, more length of stay and higher costs, etc. There are more selective drugs since there come a lot of new anti-MRSA drugs, although Vancomycin is still the main drug for MRSA associated infections. Prevention strategies for MRSA associated infections are divided into basic strategies and special strategies.

关 键 词：甲氧西林耐药金黄色葡萄球菌 抗菌药物 治疗 预防 

分 类 号：R515[医药卫生—内科学]